AU2008284352A1 - Chlamydia antigens - Google Patents

Chlamydia antigens Download PDF

Info

Publication number
AU2008284352A1
AU2008284352A1 AU2008284352A AU2008284352A AU2008284352A1 AU 2008284352 A1 AU2008284352 A1 AU 2008284352A1 AU 2008284352 A AU2008284352 A AU 2008284352A AU 2008284352 A AU2008284352 A AU 2008284352A AU 2008284352 A1 AU2008284352 A1 AU 2008284352A1
Authority
AU
Australia
Prior art keywords
fragment
sequence
seq
amino acid
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2008284352A
Other languages
English (en)
Other versions
AU2008284352A2 (en
Inventor
Todd Gierahn
Darren E. Higgins
Nadia R. Roan
Michael N. Starnbach
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harvard University
Original Assignee
Harvard University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard University filed Critical Harvard University
Publication of AU2008284352A1 publication Critical patent/AU2008284352A1/en
Publication of AU2008284352A2 publication Critical patent/AU2008284352A2/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/295—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Chlamydiales (O)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2008284352A 2007-08-03 2008-08-01 Chlamydia antigens Abandoned AU2008284352A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US96321507P 2007-08-03 2007-08-03
US60/963,215 2007-08-03
PCT/US2008/009282 WO2009020553A2 (en) 2007-08-03 2008-08-01 Chlamydia antigens

Publications (2)

Publication Number Publication Date
AU2008284352A1 true AU2008284352A1 (en) 2009-02-12
AU2008284352A2 AU2008284352A2 (en) 2010-05-27

Family

ID=40341938

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008284352A Abandoned AU2008284352A1 (en) 2007-08-03 2008-08-01 Chlamydia antigens

Country Status (7)

Country Link
US (1) US20100260791A1 (enExample)
EP (1) EP2185577A4 (enExample)
JP (1) JP2010535504A (enExample)
CN (1) CN102027003A (enExample)
AU (1) AU2008284352A1 (enExample)
CA (1) CA2695421A1 (enExample)
WO (1) WO2009020553A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9259463B2 (en) * 2006-01-16 2016-02-16 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Chlamydia vaccine
US9125863B2 (en) * 2008-05-22 2015-09-08 Children's Medical Center Corporation Synergistic immunogenic fusion protein-polysaccharide conjugate
AU2009266924B2 (en) 2008-07-01 2015-12-10 Genocea Biosciences, Inc. Antigen screening system
CN108840912B (zh) 2011-05-11 2023-07-04 儿童医疗中心有限公司 修饰的生物素结合蛋白及其融合蛋白和应用
CN110118871A (zh) * 2012-12-28 2019-08-13 塞尔雷斯蒂斯有限公司 细胞介导的免疫应答试验
BR112019019407A2 (pt) 2017-03-20 2020-05-26 Genocea Biosciences Inc. Métodos de tratamento
CN111093694A (zh) * 2017-07-13 2020-05-01 纳诺碧欧公司 衣原体纳米乳剂疫苗

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2138997C (en) 1992-06-25 2003-06-03 Jean-Paul Prieels Vaccine composition containing adjuvants
SG48309A1 (en) 1993-03-23 1998-04-17 Smithkline Beecham Biolog Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
WO1996002555A1 (en) 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US7041490B1 (en) * 1997-11-28 2006-05-09 Serono Genetics Institute, S.A. Chlamydia trachomatis polynucleotides and vectors, recombinant host cells, DNA chips or kits containing the same
EP2218732A1 (en) * 1997-11-28 2010-08-18 Merck Serono Biodevelopment Chlamydia trachomatis genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection
WO1999052549A1 (en) 1998-04-09 1999-10-21 Smithkline Beecham Biologicals S.A. Adjuvant compositions
US6248329B1 (en) * 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
US6822071B1 (en) * 1998-11-12 2004-11-23 The Regents Of The University Of California Polypeptides from Chlamydia pneumoniae and their use in the diagnosis, prevention and treatment of disease
US6565856B1 (en) * 1998-12-08 2003-05-20 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US20020061848A1 (en) 2000-07-20 2002-05-23 Ajay Bhatia Compounds and methods for treatment and diagnosis of chlamydial infection
EP2168596B1 (en) * 2001-12-12 2012-05-23 Novartis Vaccines and Diagnostics S.r.l. Immunisation against chlamydia trachomatis
GB0203403D0 (en) * 2002-02-13 2002-04-03 Chiron Spa Chlamydia cytotoxic-T cell epitopes
CA2526106A1 (en) * 2003-06-26 2005-01-13 Chiron Corporation Immunogenic compositions for chlamydia trachomatis
US8481057B2 (en) * 2005-12-22 2013-07-09 Novartis Vaccines & Diagnostics Srl Chlamydial antigens
WO2008156729A2 (en) * 2007-06-14 2008-12-24 Emergent Product Development Gaithersburg Inc. Vaccines against chlamydia infection

Also Published As

Publication number Publication date
AU2008284352A2 (en) 2010-05-27
EP2185577A4 (en) 2010-09-22
EP2185577A2 (en) 2010-05-19
WO2009020553A2 (en) 2009-02-12
WO2009020553A3 (en) 2009-04-09
JP2010535504A (ja) 2010-11-25
CN102027003A (zh) 2011-04-20
US20100260791A1 (en) 2010-10-14
CA2695421A1 (en) 2009-02-12

Similar Documents

Publication Publication Date Title
US9650423B2 (en) Long peptides of 22-45 amino acid residues that induce and/or enhance antigen specific immune responses
US20200157146A1 (en) Controlled modulation of amino acid side chain length of peptide antigens
JP4130359B2 (ja) Ｗｔ１特異的免疫療法のための組成物および方法
JP2009515831A (ja) ペスト菌（Ｙｅｒｓｉｎｉａｐｅｓｔｉｓ）抗原を含む組成物
US20100260791A1 (en) Chlamydia antigens
US20090041798A1 (en) Leishmania sterol 24-c-methyltransferase compositions for the prevention, treatment and diagnosis of leishmaniasis
JP2012180367A (ja) クラミジア感染に対するワクチン
AU2002219711A1 (en) Long Peptides of 22-45 Amino Acid Residues that Induce and/or Enhance Antigen Specific Immune Responses
JP2012512257A (ja) クラミジア抗原およびその使用
JP2010505795A (ja) クラミジア感染症に対するワクチン
CA2441947C (en) Human papilloma virus immunoreactive peptides
US20230054958A1 (en) Ctl peptide epitopes and antigen-specific t cells, methods for their discovery, and uses thereof
CA2536735C (en) Methods for determining cd8+ t-cell epitopes
TWI507413B (zh) 脂質化多抗原表位疫苗
US8637053B2 (en) Chlamydia antigens
JP2004522789A (ja) 乳頭腫ウイルスワクチン
WO2005058944A2 (en) Immunogenic peptides fragments of xage-1
EP2112157B1 (en) Long peptides of 22-45 amino acid residues that induce and/or enhance antigen specific immune responses
AU2002258614B8 (en) Human papilloma virus immunoreactive peptides
AU2002258614A1 (en) Human papilloma virus immunoreactive peptides

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 25 FEB 2010

MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted